DHR
Danaher Corporation · Healthcare · Medical - Diagnostics & Research
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 294.05K | $63.57M | n/a | −2 |
| Q2 2026 | 188 | +7 | 434.91M | $82.90B | +10 | −4 |
| Q1 2026 | 185 | -2 | 440.89M | $83.51B | +5 | −8 |
| Q4 2025 | 186 | -1 | 467.58M | $107.03B | +2 | −2 |
| Q3 2025 | 30 | -1 | 269.80M | $53.47B | +1 | −3 |
| Q2 2025 | 29 | +2 | 237.37M | $46.89B | +3 | −1 |
| Q1 2025 | 24 | -1 | 116.89M | $23.96B | +1 | −2 |
| Q4 2024 | 25 | +1 | 111.55M | $25.60B | +1 | n/a |
| Q3 2024 | 23 | +1 | 81.67M | $22.69B | +2 | −1 |
| Q2 2024 | 22 | n/a | 81.37M | $20.32B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wealth Enhancement Advisory… | 139.47K | 0.0% | $29.85M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 2 | Ninety One UK Ltd | 64.88K | +22.4% | $14.37M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 3 | TD Waterhouse Canada Inc. | 53.48K | -13.8% | $11.32M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 4 | Assenagon Asset Management S.A. | 36.22K | -53.4% | $8.02M | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Robeco Institutional Asset… | $79.00M | was 0.1% |
| Assetmark, Inc | $8.78M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 2,147 holders, 548.39M shares, $97.77B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 11.31K sh · $2.46M
Officer, Director · 39.19K sh · $8.57M
Officer, Director · 7.75K sh · $1.70M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology